» Articles » PMID: 26046523

Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection

Overview
Journal PLoS One
Date 2015 Jun 6
PMID 26046523
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Understanding the factors that delineate the efficacy of T cell responses towards pathogens is crucial for our ability to develop potent therapies against infectious diseases. Multidimensional evaluation of T cell functionality at the single-cell level enables exhaustive analysis of combinatorial functional properties, hence polyfunctionality. We have recently invented an algorithm that quantifies polyfunctionality, the Polyfunctionality Index (Larsen et al. PLoS One 2012). Here we demonstrate that quantitative assessment of T cell polyfunctionality correlates with T cell efficacy measured as the capacity to kill target cells in vitro and control infection in vivo.

Methods: We employed the polyfunctionality index on two datasets selected for their unique ability to evaluate the polyfunctional imprint on T cell efficacy. 1) HIV-specific CD8+ T cells and 2) Leishmania major-specific CD4+ T cells were analysed for their capacity to secrete multiple effector molecules, kill target cells and control infection. Briefly, employing the Polyfunctionality Index algorithm we determined the parameter estimates resulting in optimal correlation between T cell polyfunctionality and T cell efficacy.

Results: T cell polyfunctionality is correlated with T cell efficacy measured as 1) target killing (r=0.807, P<0.0001) and 2) lesion size upon challenge with Leishmania major (r=-0.50, P=0.004). Contrary to an approach relying on the Polyfunctionality Index algorithm, quantitative evaluation of T cell polyfunctionality traditionally ignores the gradual contribution of more or less polyfunctional T cells. Indeed, comparing both approaches we show that optimal description of T cell efficacy is obtained when gradually integrating all levels of polyfunctionality in accordance with the Polyfunctionality Index.

Conclusions: Our study presents a generalizable methodology to objectively evaluate the impact of polyfunctionality on T cell efficacy. We show that T cell polyfunctionality is a superior correlate of T cell efficacy both in vitro and in vivo as compared with response size. Therefore, future immunotherapies should aim to increase T cell polyfunctionality.

Citing Articles

iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA.

Yanik S, Venkatesh V, Gordy J, Alameh M, Meza J, Li Y NPJ Vaccines. 2025; 10(1):34.

PMID: 39971939 PMC: 11840135. DOI: 10.1038/s41541-025-01089-x.


Aβ-reactive T cell polyfunctionality response as a new biomarker for mild cognitive impairment.

Chiu Y, Yan S, Fan Y, Chang C, Hung R, Liu Y Alzheimers Dement (Amst). 2025; 17(1):e70042.

PMID: 39758054 PMC: 11696027. DOI: 10.1002/dad2.70042.


Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I Lancet Reg Health Eur. 2024; 48:101121.

PMID: 39624496 PMC: 11609505. DOI: 10.1016/j.lanepe.2024.101121.


A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.

Bliss C, Hulin-Curtis S, Williams M, Maruskova M, Davies J, Statkute E Mol Ther Methods Clin Dev. 2024; 32(3):101308.

PMID: 39206304 PMC: 11357811. DOI: 10.1016/j.omtm.2024.101308.


The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.

Shapiro J, Corrado M, Perry J, Watts T, Bolotin S Hum Vaccin Immunother. 2024; 20(1):2395679.

PMID: 39205626 PMC: 11364080. DOI: 10.1080/21645515.2024.2395679.


References
1.
Peters N, Pagan A, Lawyer P, Hand T, Roma E, Stamper L . Chronic parasitic infection maintains high frequencies of short-lived Ly6C+CD4+ effector T cells that are required for protection against re-infection. PLoS Pathog. 2014; 10(12):e1004538. PMC: 4256462. DOI: 10.1371/journal.ppat.1004538. View

2.
Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

3.
Radaelli A, Bonduelle O, Beggio P, Mahe B, Pozzi E, Elli V . Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine. 2007; 25(11):2128-38. DOI: 10.1016/j.vaccine.2006.11.009. View

4.
Darrah P, Patel D, De Luca P, Lindsay R, Davey D, Flynn B . Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007; 13(7):843-50. DOI: 10.1038/nm1592. View

5.
Appay V, Douek D, Price D . CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008; 14(6):623-8. DOI: 10.1038/nm.f.1774. View